gastric cancer
Conditions
Interventions
experimental group:oxaliplatin+TAS-102
Sponsors
The First Affiliated Hospital of Zhengzhou University
Eligibility
Sex/Gender
All
Age
70 Years to 100 Years
Inclusion criteria
Inclusion criteria: 1. age = 70, male or female; 2. ECoG score 0-2; 3. gastric adenocarcinoma / gastroesophageal junction adenocarcinoma diagnosed by histology or pathology; 4. TNM stage is t1-2n+m0 or t3-4nanym0; 5. there were evaluable lesions through imaging examination within 21 days before enrollment; 6. if the main organ function is normal, it meets the following criteria: (1) Blood routine examination criteria should meet: ANC = 1.5 × 109/L; PLT = 90 × 109/L; Hb= 90g/l; (2) Biochemical examination should meet the following criteria: TBIL = upper limit of normal (ULN); ALT and Ast = 1.5 times the upper limit of normal value (ULN); Alkaline phosphatase = 2.5 times the upper limit of normal (ULN); Bun and Cr = 1.5 × ULN and creatinine clearance = 50 ml/min (cockcroftgault formula); (3) Coagulation test standards should meet: international normalized ratio (INR) or prothrombin time (PT) = 1.5 × ULN, activated partial thromboplastin time (APTT) = 1.5x ULN; (4) Echocardiography and echocardiography: left ventricular ejection fraction (LVEF = 55%); (5) The QT interval (QTCF) corrected by fridericia method in electrocardiogram was <470 MS in women. Male < 450ms; 7. sign the informed consent.
Exclusion criteria
Exclusion criteria: 1. previously treated with TAS-102; 2. Previously received anti-tumor treatment or radiation therapy, excluding cured malignant tumors such as cervical carcinoma in situ, basal cell carcinoma, or squamous cell carcinoma; 3. receiving anti-tumor therapy in other clinical trials at the same time; 4. have undergone major surgical procedures within 4 weeks before enrollment, or the patient has not yet fully recovered from such surgical procedures; 5. serious heart disease or discomfort, including but not limited to the following diseases: --Confirmed history of heart failure or systolic dysfunction (LVEF 180 mmHg and / or diastolic blood pressure > 100 mmHg); 6. other situations that the researcher judged as inappropriate for inclusion;
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| pathologic complete response; | — |
Secondary
| Measure | Time frame |
|---|---|
| safety;R0 resection rate; | — |
Countries
China
Contacts
Public ContactLiu Tao
The First Affiliated Hospital of Zhengzhou University
Outcome results
None listed